Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996099006> ?p ?o ?g. }
- W2996099006 endingPage "249" @default.
- W2996099006 startingPage "242" @default.
- W2996099006 abstract "Olanzapine 10 mg added to standard antiemetic therapy including aprepitant, palonosetron, and dexamethasone has been recommended for the prevention of chemotherapy-induced nausea and vomiting. Guidelines suggest that a dose reduction to 5 mg should be considered to prevent sedation. In several phase 2 studies, olanzapine 5 mg has shown equivalent activity to olanzapine 10 mg and a favourable safety profile in relation to somnolence. We evaluated the efficacy of olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting caused by cisplatin-based chemotherapy.This was a randomised, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy of olanzapine 5 mg with triplet-combination antiemetic therapy done in 26 hospitals in Japan. Key inclusion criteria were patients with a malignant tumour (excluding those with a haemopoietic malignancy) who were scheduled to be treated with cisplatin (≥50 mg/m2) for the first time, age between 20 and 75 years, and with Eastern Cooperative Oncology Group performance status of 0-2. Eligible patients were randomly assigned (1:1) to receive either oral olanzapine 5 mg or placebo once daily on days 1-4 combined with aprepitant, palonosetron, and dexamethasone (dosage based on the standard antiemetic therapy against highly emetogenic chemotherapy). Patients were randomly assigned to interventions by use of a web entry system and the minimisation method with a random component, with sex, dose of cisplatin, and age as factors of allocation adjustment. Patients, medical staff, investigators, and individuals handling data were all masked to treatment assignment. The primary endpoint was the proportion of patients who achieved a complete response, defined as absence of vomiting and no use of rescue medications in the delayed phase (24-120 h). All randomly assigned patients who satisfied eligibility criteria received a dose of cisplatin 50 mg/m2 or more, and at least one study treatment, were included in efficacy analysis. All patients who received any treatment in this study were assessed for safety. This study is registered at UMIN Clinical Trials Registry, number UMIN000024676.Between Feb 9, 2017, and July 13, 2018, 710 patients were enrolled; 356 were randomly assigned to receive olanzapine and 354 were assigned to receive placebo. All eligible patients were observed 120 h after cisplatin initiation. One patient in the olanzapine group and three in the placebo group did not receive treatment and were excluded from all analyses. One patient in the olanzapine group discontinued treatment on day 1 and was excluded from the efficacy analysis. In the delayed phase, the proportion of patients who achieved a complete response was 280 (79% [95% CI 75-83] of 354 patients in the olanzapine group and 231 (66% [61-71] of 351 patients in the placebo group (p<0·0001). One patient had grade 3 constipation and one patient had grade 3 somnolence related to treatment in the olanzapine group.Olanzapine 5 mg combined with aprepitant, palonosetron, and dexamethasone could be a new standard antiemetic therapy for patients undergoing cisplatin-based chemotherapy.Japan Agency for Medical Research and Development." @default.
- W2996099006 created "2019-12-26" @default.
- W2996099006 creator A5000626566 @default.
- W2996099006 creator A5010130301 @default.
- W2996099006 creator A5016566770 @default.
- W2996099006 creator A5017435175 @default.
- W2996099006 creator A5030587345 @default.
- W2996099006 creator A5039401665 @default.
- W2996099006 creator A5039887744 @default.
- W2996099006 creator A5040193709 @default.
- W2996099006 creator A5061893367 @default.
- W2996099006 creator A5067881155 @default.
- W2996099006 creator A5068369923 @default.
- W2996099006 creator A5071947905 @default.
- W2996099006 creator A5072046126 @default.
- W2996099006 creator A5075027054 @default.
- W2996099006 creator A5076318118 @default.
- W2996099006 creator A5085567559 @default.
- W2996099006 creator A5087633336 @default.
- W2996099006 creator A5090846902 @default.
- W2996099006 date "2020-02-01" @default.
- W2996099006 modified "2023-10-17" @default.
- W2996099006 title "Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial" @default.
- W2996099006 cites W1569030058 @default.
- W2996099006 cites W1876492466 @default.
- W2996099006 cites W1979700184 @default.
- W2996099006 cites W1985517071 @default.
- W2996099006 cites W1992682259 @default.
- W2996099006 cites W2055125378 @default.
- W2996099006 cites W2074600725 @default.
- W2996099006 cites W2105030925 @default.
- W2996099006 cites W2116682901 @default.
- W2996099006 cites W2120970263 @default.
- W2996099006 cites W2151039173 @default.
- W2996099006 cites W2151215840 @default.
- W2996099006 cites W2460792208 @default.
- W2996099006 cites W2466185265 @default.
- W2996099006 cites W2604708549 @default.
- W2996099006 cites W2626137819 @default.
- W2996099006 cites W2765254826 @default.
- W2996099006 cites W2786363103 @default.
- W2996099006 cites W4243894673 @default.
- W2996099006 doi "https://doi.org/10.1016/s1470-2045(19)30678-3" @default.
- W2996099006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31838011" @default.
- W2996099006 hasPublicationYear "2020" @default.
- W2996099006 type Work @default.
- W2996099006 sameAs 2996099006 @default.
- W2996099006 citedByCount "96" @default.
- W2996099006 countsByYear W29960990062020 @default.
- W2996099006 countsByYear W29960990062021 @default.
- W2996099006 countsByYear W29960990062022 @default.
- W2996099006 countsByYear W29960990062023 @default.
- W2996099006 crossrefType "journal-article" @default.
- W2996099006 hasAuthorship W2996099006A5000626566 @default.
- W2996099006 hasAuthorship W2996099006A5010130301 @default.
- W2996099006 hasAuthorship W2996099006A5016566770 @default.
- W2996099006 hasAuthorship W2996099006A5017435175 @default.
- W2996099006 hasAuthorship W2996099006A5030587345 @default.
- W2996099006 hasAuthorship W2996099006A5039401665 @default.
- W2996099006 hasAuthorship W2996099006A5039887744 @default.
- W2996099006 hasAuthorship W2996099006A5040193709 @default.
- W2996099006 hasAuthorship W2996099006A5061893367 @default.
- W2996099006 hasAuthorship W2996099006A5067881155 @default.
- W2996099006 hasAuthorship W2996099006A5068369923 @default.
- W2996099006 hasAuthorship W2996099006A5071947905 @default.
- W2996099006 hasAuthorship W2996099006A5072046126 @default.
- W2996099006 hasAuthorship W2996099006A5075027054 @default.
- W2996099006 hasAuthorship W2996099006A5076318118 @default.
- W2996099006 hasAuthorship W2996099006A5085567559 @default.
- W2996099006 hasAuthorship W2996099006A5087633336 @default.
- W2996099006 hasAuthorship W2996099006A5090846902 @default.
- W2996099006 hasConcept C118552586 @default.
- W2996099006 hasConcept C126322002 @default.
- W2996099006 hasConcept C142724271 @default.
- W2996099006 hasConcept C204787440 @default.
- W2996099006 hasConcept C27081682 @default.
- W2996099006 hasConcept C2776412080 @default.
- W2996099006 hasConcept C2776619155 @default.
- W2996099006 hasConcept C2776694085 @default.
- W2996099006 hasConcept C2779924295 @default.
- W2996099006 hasConcept C2780574406 @default.
- W2996099006 hasConcept C2780580376 @default.
- W2996099006 hasConcept C2780852908 @default.
- W2996099006 hasConcept C2780884295 @default.
- W2996099006 hasConcept C42219234 @default.
- W2996099006 hasConcept C71924100 @default.
- W2996099006 hasConceptScore W2996099006C118552586 @default.
- W2996099006 hasConceptScore W2996099006C126322002 @default.
- W2996099006 hasConceptScore W2996099006C142724271 @default.
- W2996099006 hasConceptScore W2996099006C204787440 @default.
- W2996099006 hasConceptScore W2996099006C27081682 @default.
- W2996099006 hasConceptScore W2996099006C2776412080 @default.
- W2996099006 hasConceptScore W2996099006C2776619155 @default.
- W2996099006 hasConceptScore W2996099006C2776694085 @default.
- W2996099006 hasConceptScore W2996099006C2779924295 @default.
- W2996099006 hasConceptScore W2996099006C2780574406 @default.
- W2996099006 hasConceptScore W2996099006C2780580376 @default.
- W2996099006 hasConceptScore W2996099006C2780852908 @default.